"Factor VIII" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Factor VIII of blood coagulation. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin.
| Descriptor ID |
D005169
|
| MeSH Number(s) |
D12.776.124.125.350 D23.119.350
|
| Concept/Terms |
Factor VIII- Factor VIII
- Factor 8
- Coagulation Factor VIII
- Thromboplastinogen
- Blood Coagulation Factor VIII
- Factor Eight
Hyatt-C- Hyatt-C
- Hyatt C
- HyattC
- Hyate-C
- Hyate C
- HyateC
|
Below are MeSH descriptors whose meaning is more general than "Factor VIII".
Below are MeSH descriptors whose meaning is more specific than "Factor VIII".
This graph shows the total number of publications written about "Factor VIII" by people in this website by year, and whether "Factor VIII" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2008 | 0 | 2 | 2 |
| 2011 | 0 | 1 | 1 |
| 2016 | 3 | 0 | 3 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 1 | 2 |
| 2020 | 1 | 1 | 2 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Factor VIII" by people in Profiles.
-
Effects of PK-guided prophylaxis on clinical outcomes and FVIII consumption for patients with moderate to severe Haemophilia A. Haemophilia. 2023 Sep; 29(5):1234-1242.
-
Hemophilia: A Review of Perioperative Management for Cardiac Surgery. J Cardiothorac Vasc Anesth. 2022 01; 36(1):246-257.
-
Comparing Physician and Patient Perspectives on Prophylactic Treatment with BAY?94-9027 for Severe Haemophilia?A: A Post Hoc Analysis. Adv Ther. 2020 06; 37(6):2763-2776.
-
Blood-induced bone loss in murine hemophilic arthropathy is prevented by blocking the iRhom2/ADAM17/TNF-a pathway. Blood. 2018 09 06; 132(10):1064-1074.
-
Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement. J Thromb Haemost. 2018 04; 16(4):778-790.
-
Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis. J Thromb Haemost. 2018 01; 16(1):39-43.
-
Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A. Blood. 2017 03 09; 129(10):1245-1250.
-
Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate(?) ) in patients with severe haemophilia A. Haemophilia. 2016 Sep; 22(5):730-8.
-
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. N Engl J Med. 2016 May 26; 374(21):2054-64.
-
Exploring the biological basis of haemophilic joint disease: experimental studies. Haemophilia. 2012 May; 18(3):310-8.